FRATES JAMES M (Chief Financial Officer) sold 2.0% of their position (3.56K shares) of AMYLYX PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $52.1K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/4/2026ACC: 0001193125-26-037553
Officer· Chief Financial Officer
Since Jan 2022
-3.56K
Net shares
Net seller
$52.1K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
3.56K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−3.56K
Price / share
$14.65
Trade value
$52.10K
% of position
2.0%
2/2/2026
177.10K→173.55K
Total
Net shares
−3.56K
Net value
-$52.10K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/2/2026 | S · Sale | −3.56K | $14.65 | $52.10K | 2.0% | 177.10K | 173.55K |
| Total | −3.56K | -$52.10K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)3
Common Stock
IndirectShares owned11.07K
Common Stock
IndirectShares owned100K
Common Stock
IndirectShares owned15.46K
Total
126.53K indirect126.53K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 11.07K | Indirect |
| Common Stock | 100K | Indirect |
| Common Stock | 15.46K | Indirect |
| Total | 126.53K | 126.53K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported